Tyvaso Dpi was United Therapeutics’s largest product and service line in fiscal 2025, bringing in $1.29B of $3.18B (41%).
| Product and Service | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyvaso Dpi | $158.30M | $731.10M | $1.03B | $1.29B | |||||||||||||
| Nebulized Tyvaso | $714.70M | $502.60M | $586.80M | $585.70M | |||||||||||||
| Remodulin | $500.20M | $494.80M | $538.10M | $526.80M | |||||||||||||
| Tyvaso | — | — | — | — | |||||||||||||
| Orenitram | $325.10M | $359.40M | $434.30M | $496.90M | |||||||||||||
| Adcirca | $41.30M | $28.90M | $23.80M | $30.00M | |||||||||||||
| Unituxin | $182.90M | $198.90M | $238.70M | $226.80M | |||||||||||||
| Other | $13.80M | $11.80M | $22.10M | $24.00M | |||||||||||||
| Total | $1.94B | $2.33B | $2.88B | $3.18B |
United Therapeutics brought in $3.18B from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 10.6% from $2.88B in fiscal 2024. Tyvaso Dpi was the largest at $1.29B (40.6%), ahead of Nebulized Tyvaso at $585.70M (18.4%) and Remodulin at $526.80M (16.6%). The other four lines brought in $777.70M combined.
Compared with fiscal 2024, Tyvaso Dpi grew fastest, up 25.0% to $1.29B, while Unituxin fell the most, down 5.0% to $226.80M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.94B to $3.18B, a compound annual growth rate of 18.0%. Tyvaso Dpi's share of the total rose from 8.2% to 40.6%.
United States was United Therapeutics’s largest region in fiscal 2025, bringing in $3.04B of $3.18B (95%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.81B | $2.20B | $2.74B | $3.04B | |||||||||||||
| Us | — | — | — | — | |||||||||||||
| Rest-Of-World | $122.20M | $125.30M | $137.70M | $145.70M | |||||||||||||
| European Union & Others | — | — | — | — | |||||||||||||
| Segment Geographical Groups Of Countries Group One | — | — | — | — | |||||||||||||
| Total | $1.94B | $2.33B | $2.88B | $3.18B |
United Therapeutics brought in $3.18B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 10.6% from $2.88B in fiscal 2024. United States was the largest at $3.04B (95.4%), ahead of Rest-Of-World at $145.70M (4.6%).
Compared with fiscal 2024, United States grew 10.9% to $3.04B and Rest-Of-World grew 5.8% to $145.70M. From fiscal 2022 to 2025, combined revenue from these regions grew from $1.94B to $3.18B, a compound annual growth rate of 18.0%. United States' share of the total rose from 93.7% to 95.4%.
United Therapeutics (UTHR) reports its revenue by product and service and by geography. In fiscal 2025, Tyvaso Dpi was its largest product and service line, bringing in $1.29B (40.6% of the total), followed by Nebulized Tyvaso at $585.70M (18.4%).
Tyvaso Dpi was United Therapeutics' largest product and service line in fiscal 2025, bringing in $1.29B, or 40.6% of the $3.18B total across its seven product and service lines.
United States was United Therapeutics' largest region in fiscal 2025, bringing in $3.04B, or 95.4% of the $3.18B total across its two regions.
Among United Therapeutics' product and service lines that make up at least 2% of revenue, Tyvaso Dpi grew fastest in fiscal 2025, up 25.0% from $1.03B to $1.29B.
Every figure comes from United Therapeutics' annual financial filings, as reported. Each line keeps the name United Therapeutics gives it, and years follow its fiscal calendar.
United Therapeutics' revenue by product and service goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.